Park Avenue Securities LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 22.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,736 shares of the medical research company’s stock after purchasing an additional 2,851 shares during the period. Park Avenue Securities LLC’s holdings in IQVIA were worth $4,231,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. Financial Freedom LLC purchased a new position in IQVIA during the first quarter worth $25,000. Ascentis Independent Advisors acquired a new position in shares of IQVIA in the first quarter worth $25,000. Compass Financial Management LLC purchased a new stake in shares of IQVIA in the second quarter valued at $27,000. Elevation Wealth Partners LLC lifted its position in shares of IQVIA by 218.8% in the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 105 shares in the last quarter. Finally, Pension & Wealth Management Advisors Inc. purchased a new stake in shares of IQVIA in the third quarter valued at $30,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.
IQVIA Price Performance
IQV stock opened at $274.83 on Friday. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $284.50. The stock’s fifty day simple moving average is $266.01 and its 200-day simple moving average is $210.28. The company has a quick ratio of 0.71, a current ratio of 0.83 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $45.29 billion, a price-to-earnings ratio of 24.10, a price-to-earnings-growth ratio of 2.45 and a beta of 1.17.
IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The business had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the previous year, the business earned $3.00 earnings per share. The business’s revenue for the quarter was up 8.0% on a year-over-year basis. Equities research analysts expect that IQVIA Holdings Inc. will post 11.56 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on the company. Argus lifted their price objective on IQVIA from $215.00 to $235.00 in a research report on Tuesday, July 7th. Truist Financial upped their target price on shares of IQVIA from $329.00 to $346.00 and gave the company a “buy” rating in a report on Wednesday. William Blair raised shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Leerink Partners raised their price target on shares of IQVIA from $280.00 to $310.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Finally, Stifel Nicolaus lifted their price target on shares of IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $294.21.
View Our Latest Stock Analysis on IQV
Insider Activity
In other news, insider W. Richard Staub sold 5,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider James G. Berkshire sold 2,668 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the transaction, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.70% of the stock is owned by insiders.
About IQVIA
IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.
Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.
Featured Articles
- Five stocks we like better than IQVIA
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
